Loading...
Market
What will be Novo Nordisk's CEO response to the reprimand by the end of 2024?
2
Resolution / Starting Odds
Public apology • 25%
Denial of wrongdoing • 25%
Commitment to improve transparency • 25%
No comment • 25%
Official statements from Novo Nordisk or media interviews
Story
Novo Nordisk Reprimanded by UK Regulators for £7.8 Million Undisclosed Payments
Jul 5, 2024, 02:16 PM
Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organizations in the healthcare sector in Britain. The undisclosed payments amount to approximately £7.8 million.
View original story
Similar markets
Significant price reduction • 25%
Minor price reduction • 25%
No price reduction • 25%
Other • 25%
Acknowledge risk and issue warning • 25%
Deny risk and continue marketing • 25%
Initiate further studies • 25%
Discontinue affected products • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Yes • 50%
No • 50%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Seek further trials • 25%
Submit for regulatory approval • 25%
Discontinue development • 25%
Partner with another company • 25%
No action taken • 25%
Recommendations for price reductions • 25%
Legislation introduced • 25%
Other • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Change within +/- 5% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%